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Purpose: To evaluate the penetration of carbon nanotubes (CNTs) throughout retinoblastoma in a transgenic mice model.
Methods: CNTs functionalized with fluorescein isothiocyanate and targeting ligands biotin (CTN-FITC-Bio, 0.5mg/ml), or
folic acid (CNT-FITC-FA, 0.5mg/ml) were injected into the vitreous of one eye of LHBETATAG transgenic mice. Other eye did
not receive any injection and was used as control. Three mice were sacrificed at days 1, 2, and 3. Eyes were enucleated
and stained with 4,6-diamidino-2-phenylindole. The sections were imaged by fluorescent microscope. The images were
transformed into grey-scale in MATLAB for intensity analysis. Background intensity was normalized by marking squares
outside the eyeball and using themean intensity of these squares. Fluorescent intensity (FI) for each imagewasmeasured
by calculating the intensity of a same-sized square within retinoblastoma.
Results: Nine eyes of nine mice were included in each CNT-FITC-Bio and CNT-FITC-FA groups. The mean FI in CNT-FITC-
Bio was 52.08 ± 6.33, 53.62 ± 9.00, and 65.54 ± 5.14 in days 1, 2, and 3, respectively. The mean FI in CNT-FITC-FA was
50.28 ± 7.37, 59.21 ± 6.43, and 58.38 ± 2.32 on days 1, 2, and 3, respectively. FI was significantly higher in eyes injected
with CNT-FITC-Bio and CNT-FITC-FA compared to the control eyes (P = 0.02). There was no difference in FI between eyes
with CNT-FITC-Bio and CNT-FITC-FA, and FI remained stable on days 1–3 in CNT-FITC-Bio, CNT-FITC-FA, and control eyes
(P > 0.05).
Conclusion: We observed higher FI in eyes with CNT-FITC-Bio and CNT-FITC-FA compared to control eyes, showing
penetration of CNTs throughout retinoblastoma. CNTs can be a carrier candidate for imaging or therapeutic purposes in
retinoblastoma.
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Retinoblastoma, a potentially deadly cancer, is the
most common intraocular cancer of childhood.[1]
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Within the last decade, the use of intraarterial
and intravitreal chemotherapies significantly
changed the management of retinoblastoma.
Prior to intraarterial chemotherapy, systemic
chemotherapy provided almost 100% globe
salvage in group A, B, and C eyes when coupled
with laser and cryotherapy and 48% in group
D eyes.[2–4] The beneficial effect of intraarterial
chemotherapy was more pronounced in group D
eyes by improving the globe salvage rate up to
100%.[5–8] However, advanced group D eyes with
vitreous seeds and group E eyes continued to
be a challenging problem. The use of intravitreal
injection especially improved the globe salvage
rate in group D eyes with extensive vitreous seeds
and group E eyes increasing the globe salvage rate
from 27% to 73%.[9] The recurrence of main tumor
rather than vitreous seeds was reported to be the
reason of failure in globe salvage, suggesting the
lack of penetration of chemotherapeutic agents in
the main tumor.[10]
Carbon nanotubes (CNTs) are unique tubular,
hollow nanostructures that have been extensively
utilized in biomedical applications including
implantable devices.[11, 12] They can be single-
walled, double-walled, or multi-walled with
diameters from < 1 nm up to 100 nm and lengths
from 100 nm to microns. In vivo and in vitro studies
showed that CNTs have efficient drug-loading
capacity with high length/diameter ratio and
multifunctional surface chemistry.[11–14] In addition,
they are biocompatible.[11, 13, 14] All these features
make CNTs an ideal candidate for consideration
for drug delivery or tumor imaging. The most of
current biodistribution data of CNTs has been
obtained based on the systemic administration in
animal models.[15, 16] By using a three-dimensional
(3D) hepatocellular carcinoma tissue culture, Wang
et al[17] showed that the surface of CNTs can be
engineered to enable deep and fast penetration
into tissues. This is achieved by combining the
classical 3D diffusion through the interstitial gaps
with accelerated two-dimensional (2D) diffusion
of the CNTs over the cellular membranes. The
combination of deep penetration into the tumor
with the ability of CNTs to carry anticancer
drugs make them promising candidates for both
the diagnostics and treatment of hard-to-reach
intraocular tumors.
Retinoblastoma cells have a specialized high
affinity carrier-mediated system for folic acid and
biotin uptake.[18, 19] Therefore, folic acid and biotin
can be ideal targets to increase CNTs uptake.
In this study, we injected CNTs functionalized
with ligands fluorescein isothiocyanate (FITC) and
folic acid (CNT-FITC-FA) or biotin (CNT-FITC-Bio)
into the vitreous of one eye with LHBETATAG
transgenic retinoblastoma model and compared
the fluorescein intensity between the injected and
uninjected control eyes to evaluate the ability
of CNTs to penetrate through the retinoblastoma
tumor when injected intravitreally.
METHODS
Animals
All experiments are performed in accordance
with the Association for Research in Vision
and Ophthalmology (ARVO) statement for
the Use of Animals in Ophthalmic and Visual
Research. The protocol was approved by the
University Committee on Use and Care of Animals
of the University of Michigan. All surgeries
were performed under ketamine and xylazine
anesthesia, and all efforts were made to minimize
suffering. We used the LHBETATAG transgenic mice
as retinoblastoma animal mode at 8–10 weeks
old. Eye tumors in the LHBETATAG transgenic
mouse model showed the histological features
of human retinoblastoma with endophytic and
exophytic growth with invasion of the retina,
choroid, and optic nerve.[20] This animal model
has been extensively characterized and develops
bilateral multifocal retinal tumors that are stable
and grow at the predictable rate.[20] In this model,
retinoblastoma develops when the mice is about
six weeks old. When the mice reach the age of
8–10 weeks, about half of the globe is filled with
the tumor, and at the age of 12–14 weeks, the
entire mice globe is filed with retinoblastoma.
Examination of each mice was performed and
it was confirmed that retinoblastoma tumor fills
about 50% of the globe.
Preparation of targeted carbon nanotubes
functionalized with fluorescein isothiocyanate
and biotin (CNT-FITC-Bio), and fluorescein
isothiocyanate and folic acid (CNT-FITC-FA)
CNTs were targeted by covalent attachment
of biotin and folic acid. Receptors for biotin
and folic acid are more highly overexpressed
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on retinoblastoma cells than retinal pigment
epithelium.[21] They were also attached with FITC
to image them and to evaluate their penetration. In
short, 0.5 mg CNTs with an average diameter of 1.2
nm and a length of 1000 nm (0.5 mg/mL, P3SWNT
with 1.0–3.0 atomic % carboxylic acid, Carbon
Solutions, Inc.) were dispersed in phosphate-
buffered saline (PBS) buffer followed by incubation
with 8 mg of 1-ethyl-3-(3-(dimethylamino)propyl)
carbodiimide (EDAC) for 1 min at room temperature,
after which samples were immediately vortexed.
Next, Biotin and FITC (Life Technologies, CA) (2
μg in 20 μL of dimethylformamide) were added
together, and the resulting mixture was allowed
to react for an additional 2 hours at 37°C in a
rotator rocker. These samples were then washed
by PBS and centrifuged at 1300 rpm for 20 min
for three times to remove unbound antibodies
and excess FITC in Centricon YM-50 tubes
(MilliporeSigma, MA), and the resulting CNT-FITC-
Bio were suspended in 1 mL of serum-free Eagle’s
Minimum Essential Medium (EMEM) and used
immediately. Similar procedure was applied to
prepare CNTs functionalized with folic acid to
prepare the CNT-FITC-FA.
Surgical Technique
In this experiment, 1 µl of 0.5 mg/mL targeted CNT-
FITC-Bio, and CNT-FITC-FA were injected into the
vitreous of one eye of LHBETATAG transgenic mice.
The other eye was not injected and was used as
control. In each group of CNT-FITC-Bio (nine eyes)
and CNT-FITC-FA (nine eyes), nine eyes of nine
mice were used. The control group comprised the
uninjected eyes of nine mice. Vitreous injections
were performed by an experienced team member
(CL) under direct visualization with the operating
microscope, after dilating the pupil and confirming
that injection was into the vitreous cavity, but not
into the tumor. During the procedure, the tip of the
needle was constantly monitored. Threemice were
sacrificed at each day 1, 2, and 3, and eyes were
enucleated.
Histopathological Preparation
Mice eyes were fixated with 10% formaldehyde
in phosphate-buffered saline (PBS) for histology
or with 4% paraformaldehyde in PBS followed by
incubating with 30% sucrose in PBS. Eyes were
embedded in optimal cutting temperature (OCT)
compound and cryosectioned. They were stained
with 4,6-diamidino-2-phenylindole (DAPI, 1 mg/mL
in PBS; Sigma-Aldrich) to visualize cell nuclei.
Image Analysis
Each globe was sectioned in to 5 µm thick
sections. Five sections from each globe were
evaluated and count of these five sections were
averaged. The stained sections were imaged by
Olympus BX-51 fluorescent microscope under 10×
magnification. The fluorescent CNTs were excited
by 480 nm light with the same laser power and the
camera exposure was kept the same all the time
(which is 102.6 ms). The images were transformed
into grey-scale images in MATLAB for intensity
analysis. In order to compare the intensity, all
the images were normalized. For normalization,
a blue square region (blue square marked in
Figure 1) outside the eyeball area was marked in
each eye, and the mean intensity within these
same-sized blue squares were calculated for each
eye. It is understandable that the glass region
should reflect same, fixed light intensity. Therefore,
all the images were normalized by setting the
mean intensity of these blue squares to be the
same. Finally, the fluorescent intensity (FI) for each
image was calculated by calculating the intensity
of a same-sized red square region (red square
marked in Figure 1) within the eyeball area. We
avoided the muscle cell area which could also
show strong fluorescents. It is worth noting that
the size of this square was determined by the
largest possible area among the images. In order
to compensate the false-positive results resulting
from the photoconversion of DAPI due to blue
excitation and green emission as reported by Jez
et al,[22] we analyzed both control and injected
eyes, and compared them with each other.
Statistical Analysis
The Difference in the fluorescein intensity between
eyes injected with CNT-FITC-Bio and CNT-FITC-
FA, and the control eyes were compared by using
the Mann–Whitney U test. Similarly, the difference
in the fluorescein intensity between eyes injected
with CNT-FITC-FA and CNT-FITC-Bio were also
compared by using Mann-Whitney U test. The
change in the fluorescein intensity in eyes injected
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Figure 1. (A) From left to right, eyes injected with CNT-FITC-Bio on days 1, 2, and 3 and control eye (×10, DAPI). (B) From left to
right eyes injected with CTN-FITC-FA on days 1, 2, and 3 and control eye (×10, DAPI). The blue squares in each image denotes
the area in glass region, which is used for normalization. The red squares were used to calculate the averaged intensity within
tumor. FITC-functionalized CNTs appear as bright spots throughout the retinoblastoma tumor in colored images.
Figure 2. The change of average intensity of CNTs functionalized with fluorescein isothiocyanate and biotin, and fluorescein
isothiocyanate and folic acid over the time.
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with CNT-FITC-FA and CNT-FITC-Bio and control
eyes at different days were evaluated by using
repeated measures ANOVA test.
RESULTS
Nine eyes of ninemicewere included in each group
of CNT-FITC-Bio and CNT-FITC-FA. In all eyes of
LHBETATAG transgenic mice, retinoblastoma tumor
occupied about 50% ofmice eye.We found that the
fluorescence intensity was higher in retinoblastoma
tumor in eyes injected with CNT-FITC-FA and CNT-
FITC-Bio than the uninjected control eyes (Table
1). The FI in the retinoblastoma tumor remained
about the same on days 1 and 2, and mildly
increased on day 3 for CNT-FITC-Bio (Figure 1A).
The FI increased on day 2 and remained about
the same on day 3 for CNT-FITC-FA (Figure 2). We
also observed that both CNT-FITC-Bio and CNT-
FITC-FA passed through the retinoblastoma and
stained the retinal pigment epithelium, showing
their penetration through the tumor (Figure 1B). The
mean fluorescein intensity was significantly higher
in eyes injected with CNT-FITC-Bio and CNT-FITC-
FA compared to the uninjected control eyes (P =
0.02). We did not observe any difference in the
mean fluorescein intensity between CNT-FITC-Bio
and CNT-FITC-FA groups (P > 0.05). There was no
significant change in the fluorescein intensity at
different days in eyes injected with CNT-FITC-Bio
and CNT-FITC-FA and the uninjected control eyes
(P > 0.05).
Beside the tumor, we did not observe staining
in the lens, iris, or cornea. There was no dose- or
procedure-related complications (cataract or retinal
detachment).
DISCUSSION
Carbon nanotubes have gained tremendous
attention as drug carriers or imaging tools due to
their unique characteristics such as high surface
area, enhanced cellular uptake, and the possibility
to be easily conjugated with many therapeutic
or diagnostic agents.[15–17] Previous studies about
CNTs were usually based on animal studies or 3D
tissue cultures.[15–17] In these studies, CNTs were
delivered systemically to the tumor through the
blood vessels and penetrated through the vessel
walls or added to the 3D tissue culture medium.
In this study, intravitreal CNTs penetrated and
passed through the retinoblastoma tumor and
reached the retinal pigment epithelium layer. This
was the first study that showed that CNTs can
penetrate and diffuse through a solid tumor such
as retinoblastoma when injected intravitreally.
Wang et al[17] investigated the diffusional transport
of CNTs in 3D tissue replica of hepatocellular
carcinoma and found that diffusion coefficients of
CNTs were high and comparable to the diffusion
rates of similarly chargedmolecules with molecular
weights 10000x lower. The diffusivity of CNTs in
tissues was enhanced after functionalization with
transforming growth factor β1. The high diffusion
coefficient was attributed to the planar diffusion
of CNTs along cellular membranes reducing
effective dimensionality of diffusional space and
electrostatic repulsion between CNT and cellular
membrane. Although the penetration of CNTs
remained stable on the first and second days in
the eyes injected with CNT-FITC-Bio with mild
increase on day 3, and the penetration increased
on day 2 and remained stable on day 3 in eyes
injected with CNT-FITC-FA, these changes were
not found to be statistically significant. Studies with
larger number of animals and longer follow-up are
needed to confirm these findings and if CNTs will
remain stable inside the retinoblastoma over time.
With the introduction of well-tolerated intravitreal
injection technique in retinoblastoma, intravitreal
chemotherapy gained an attention by improving
the control of vitreous seeds which were the
main reason of treatment failures.[23–25] Abramson
et al[26] reviewed eyes treated with intravitreal
chemotherapy for indications other than vitreous
seeds including subretinal seeds and recurrent
retinal tumors in 56 eyes of 52 patients and
found the recurrence rate of retinal tumors in
19% of eyes and subretinal seeds in 11% of eyes.
They concluded that intravitreal chemotherapy
could be considered as adjuvant therapy in globe-
sparing treatment. The penetration and diffusion
of CNTs in retinoblastoma in animal models
suggest that they could be an ideal carrier for
chemotherapeutic agents in retinoblastoma. This
might provide treatment of vitreous or subretinal
seeds or retinoblastoma.
There are some limitations of our study. This was
a pilot study that was performed in small numbers
of animals and these eyes were evaluated on days
1, 2, and 3. We did not do any electron microscopy
to show the distribution of CNTs. However, higher
fluorescein intensity throughout retinoblastoma
450 JOURNAL OF OPHTHALMIC AND VISION RESEARCH VOLUME 15, ISSUE 4, OCTOBER-DECEMBER 2020
Penetration of Carbon Nanotubes into Retinoblastoma; Demirci et al
Table 1. Averaged intensities measured in eyes injected with CNT-FITC-Bio and CNT-FITC-FA





















*The fluorescein intensity was significantly higher in eyes injected with CNT-FITC-Bio and CNT-FITC-FA compared to the control
uninjected eyes (p = 0.02).
**There was no difference in fluorescein intensity between CNT-FITC-Bio and CNT-FITC-FA groups (p > 0.05).
***There was no significant change in fluorescein intensities at different days in the eyes with CNT-FITC-Bio and CNT-FITC-FA
and the uninjected control eyes (p > 0.05).
tumors showed that CNTs have significantly higher
penetration throughout the retinoblastoma tumors.
In this study, we did not evaluate the distribution of
CNTs on the other ocular structures in detail as well
as their toxicities. Future studies will be needed to
address these issues.
In conclusion, we showed that CNTs can
penetrate through the retinoblastoma tumor
in a transgenic retinoblastoma model when
administrated into the vitreous. There was no
difference in tumor penetration between the
CNT-FITC-Bio and CNT-FITC-FA groups. The deep
penetration into the tumor with the ability of CNTs
to carry chemotherapeutic agents make them
promising carrier candidates for both diagnostics
and treatment of these hard-to-reach intraocular
tumors.
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